Skip to main content

Part of UT Health San Antonio

UT Health San Antonio PhysiciansUT Health San Antonio Physicians

Part of Long School of Medicine

Search

Quicklinks

Contact Us 210-450-9000

 

Patient Information

  • About Us
  • MyChart Login
  • What is MyChart?
  • Pay Bill Online
  • Phone Directory
  • Medicare Annual Wellness Visits
  • Major Insurance Plans
  • Medical Records Request

Physician Information

  • Careers
  • Epic Login

 Close Quicklinks

Menu
  • Find Provider
  • Services
  • Health Library
  • Primary Care
  • Specialty Practices
  • Locations
  • Make Appointment
  • MyChart

You are here

  • Providers Directory
  • John Sarantopoulos

John Sarantopoulos, M.D.

Practice Locations

  • Hematology - Mays Cancer Center
    210-450-1000

If you're a patient of John Sarantopoulos, M.D., and a MyChart user, you can:

Send message via MyChart

Request appointment via MyChart

Specialties

    • Medical Oncology
    • Internal Medicine

Other Languages Spoken

  • French, Spanish
John Sarantopoulos M.D.

Dr. John Sarantopoulos is a clinical research investigator and medical oncologist, with a full-time faculty appointment as assistant professor of medicine in the division of hematology-oncology at UT Health San Antonio. His clinical interests and expertise are in early antineoplastic drug development and evaluation for human solid tumors including genitourinary malignancies of renal, prostate, bladder and melanoma. He is involved with the Cancer Therapy & Research Center’s early therapeutics phase I program, and is a member of the experimental developmental therapeutics program.

Dr. Sarantopoulos completed an advance drug development fellowship and is presently focusing on early phase I/II trials. He has been a co-principal investigator and principal investigator in over 54, phase I solid tumor studies, including first in human studies or first in class compounds, food effect or bioequivalence studies, drug interaction studies, QTc effect studies, and organ dysfunction studies, including renal and hepatic impairment. Studies have included National Cancer Institute cancer therapy evaluation program studies and the NCI organ dysfunction working group and cooperative group trials including the Southwest Oncology Group, where he is a member of the early therapeutics and genitourinary committees, as well as industry-sponsored and cancer center investigator-initiated trials.

In addition, he has been a sub investigator in over 139 trials in this area at the CTRC over the last several years. Dr. Sarantopoulos’ education, clinical and research experiences place him in a select group of investigators that can complete complex early phase trials that are important to the development of new treatments for patients with cancer.

Publications

Curtis, K. K., Sarantopoulos, J., Northfelt, D. W., Weiss, G. J., Barnhart, K. M., Whisnant, J. K., Leuschner, C., Alila, H., Borad, M. J. & Ramanathan, R. K. Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors. Cancer Chemother. Pharmacol. 73(5):931-41 (2014). PMID: 24610297; PMCID: PMC4000412

Falchook, G. S., Venkatakrishnan, K., Sarantopoulos, J., Kurzrock, R., Mita, A. C., Fu, S., Mita, M. M., Zhou, X., Jung, J. A., Ullmann, C. D., Milch, C. & Rosen, L. S. Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors. Int. J. Clin. Pharmacol. Ther. 53, 563-572 (2015). PMID: 26073352

Kurzrock, R., Gabrail, N., Chandhasin, C., Moulder, S., Smith, C., Brenner, A., Sankhala, K., Mita, A., Elian, K., Bouchard, D. & Sarantopoulos, J.  Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. Molecular Cancer Therapeutics 11(2):308-16. doi: 10.1158/1535-7163.MCT-11-0566 (2012). PMID:22203732

Education

Medical School: 
University of Manitoba
Residency: 
University of Calgary
Fellowship: 
University of Calgary

Qualifications

Board Certification:
  • American Board of Internal Medicine/Medical Oncology
  • American Board of Internal Medicine

Research Interests

Clinical Trials, Lymphoma, Sarcoma

Experimental and Developmental Therapeutics Program 

Dr. John Sarantopoulos' research profile
More about this provider

  • CTRC at UT Health Science Center offers practical course on new cancer drugs


map to UT Health Physician Practice

Physicians and care providers of UT Health San Antonio

8300 Floyd Curl Dr.
San Antonio, TX 78229

210-450-9000

 

Connect with us

  • Facebook
  • Twitter
  • About Us
  • Contact Us
  • Careers
  • Phone Directory
  • Maps & Directions
  • Patient Rights and Responsibilities
  • Language Assistance